Gilead Sciences, Inc. GILD
150.93
1.24
0.83%
as of 25 Sep
- Market cap
- $183.2B
- P/E
- 0.0×
Follow GILD
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Gilead Sciences, Inc. (GILD) P/E ratio
Gilead Sciences, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (September 2026) to 979× (November 2024) — the current reading is the lowest in ten years.
P/E ratio, daily
Annual
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 17.9× | (92.63%) |
| FY2024 | 243× | 1,228.70% |
| FY2023 | 18.3× | (21.37%) |
| FY2022 | 23.3× | 58.62% |
| FY2021 | 14.7× | (97.48%) |
| FY2020 | 583× | 3,701.51% |
| FY2019 | 15.3× | 2.90% |
| FY2018 | 14.9× | (28.85%) |
| FY2017 | 20.9× | 184.52% |
| FY2016 | 7.4× | (10.14%) |
Quarterly
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 18.8× | 4.83% |
| Dec 2025 | 17.9× | 5.25% |
| Sep 2025 | 17.0× | (22.30%) |
| 42 more quarters | Free account |
Against its own ten years
Low 0.0×
High 979×
Ten-year median
17.3×
Current reading's percentile
4
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| GILD Gilead Sciences, Inc. | n/m |
| NVO Novo Nordisk A/S compare | 9.5× |
| BMY Bristol Myers Squibb Company compare | 13.8× |
| GSK GSK PLC Sponsored ADR compare | 15.3× |
| SNY Sanofi compare | 21.5× |
| NVS Novartis AG compare | 21.8× |
| AZN AstraZeneca PLC compare | 24.7× |
| AMGN Amgen Inc. compare | 25.6× |
| PFE Pfizer Inc. compare | 37.7× |
| Drug Manufacturers General industry median | 24.7× |
| Healthcare sector median | 22.7× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on GILD
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement